Capricor Therapeutics Inc
CAPRCapricor Therapeutics Inc (CAPR) is a biotechnology company focused on developing cell-based therapeutics for rare and significant diseases, particularly in the areas of cardiology and other unmet medical needs. The company's primary focus is on regenerative medicine, utilizing its proprietary cell therapy platform to develop treatments aimed at repairing and regenerating damaged tissues.
Company News
DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in l...
Karen Krasney, EVP and General Counsel of Capricor Therapeutics, exercised and sold 25,000 stock options for approximately $793,000 on May 1, 2026, reducing her direct equity position by 45%. The sale was executed under a pre-scheduled 10b5-1 trading plan established in December 2025, indicating a diversification move rather than a loss of confid...
Capricor Therapeutics announced positive Phase 3 HOPE-3 trial results for its cell therapy candidate deramiocel, causing its stock to surge dramatically. Martin Shkreli, who had previously predicted the trial's failure, criticized the data and claimed the company changed its primary endpoint.
Capricor Therapeutics met with the FDA to discuss regulatory approval for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy. The FDA provided clarity on the approval process and showed flexibility in reviewing trial data, causing the stock to surge.
Capricor Therapeutics received a Complete Response Letter from the FDA denying its Biologics License Application for deramiocel, causing a significant stock price drop and triggering a potential securities class action lawsuit.
